Iridex Reports Third Quarter 2026 Financial Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iridex (IRIX) reported third-quarter 2026 revenue of $10.2 million and reduced its full-year revenue outlook amid weaker international demand. Revenue fell 19% year over year in the quarter ended October 3, 2026. Retina revenue was $5.1 million, versus $6.7 million, while Cyclo G6 revenue was $3.2 million, versus $3.5 million.
Gross margin rose to 42.4% from 32.1%, and net loss narrowed to $1.4 million, or $0.08 per share, from $1.6 million, or $0.09 per share. Cash totaled $3.7 million, down $1.0 million from July 4, 2026. Iridex cut its 2026 revenue guidance to $46 million–$48 million from $51 million–$53 million, excluding Middle East revenue, and maintained adjusted operating expense guidance of $19 million–$19.5 million. The company expects its completed headquarters relocation to save approximately $600,000 annually.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter gross margin increased to 42.4%, versus 32.1% a year earlier and 34.2% in second-quarter 2026.
- Moderate pointThird-quarter net loss narrowed to $1.4 million, or $0.08 per share, from $1.6 million, or $0.09.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Headquarters relocation completed; Iridex expects approximately $600,000 in annualized savings.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Contract manufacturing transition is expected to drive further margin expansion through 2027.
- Minor pointU.S. glaucoma business growth partially offset lower international retina sales and probe orders.
4 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter cash utilization is expected to decrease significantly with stronger sales and consumption of safety stock inventory.
- Minor pointProduct-line review is reprioritizing resources toward opportunities Iridex considers most profitable.
- Minor pointNine-month net loss narrowed to $3.191 million, or $0.18 per share, from $4.253 million, or $0.25.
- Minor pointNine-month operating expenses declined to $15.855 million from $16.306 million.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.2026 revenue guidance cut to $46 million–$48 million from $51 million–$53 million; Middle East revenue remains excluded.
- Moderate pointThird-quarter revenue fell 19% year over year to $10.2 million from $12.5 million.
- Moderate pointThird-quarter adjusted EBITDA loss widened to $580,000 from $131,000 a year earlier.
- Moderate pointCash and cash equivalents fell $1.0 million from July 4, 2026, to $3.7 million.
- Moderate pointInventories increased to $11.760 million from $7.877 million at January 3, 2026.
- Moderate pointStockholders’ equity declined to $2.627 million from $4.922 million at January 3, 2026.
9 minor points
- Minor pointRetina revenue declined to $5.1 million from $6.7 million a year earlier.
- Minor pointCyclo G6 revenue declined to $3.2 million from $3.5 million a year earlier.
- Minor pointCyclo G6 probe sales were approximately 11,900, compared with 14,900 a year earlier.
- Minor pointCyclo G6 system sales declined to 28 from 30 a year earlier.
- Minor pointOther revenue declined to $1.9 million from $2.2 million, reflecting lower service revenue and absent royalties.
- Minor pointInternational orders faced distributor inventory reductions, late-quarter delays and ongoing regulatory challenges.
- Minor pointThird-quarter operating expenses increased to $5.465 million from $5.424 million a year earlier.
- Minor pointNine-month revenue declined to $34.521 million from $37.951 million.
- Minor pointNine-month adjusted EBITDA shifted to a $674,000 loss from a $305,000 profit.
News Explained
Even excluding the prior-year write-off, Iridex reported a 370-basis-point gross-margin improvement.
In its third-quarter report, Iridex said cash use was
The comparison showing gross margin at
Key Figures
- Q3 revenue
- $10.2 million; down 19%
- Q3 2026 compared with Q3 2025
- Pro forma gross margin
- 38.7%; 370 basis point improvement
- Excludes the impact of a one-time write-off recorded in Q3 2025
- Net loss
- $1.4 million, or $0.08 per share
- Q3 2026; compared with $1.6 million, or $0.09 per share, in Q3 2025
- Adjusted EBITDA loss
- $0.6 million
- Q3 2026; compared with a $0.1 million loss in Q3 2025
- 2026 revenue guidance
- $46 million to $48 million
- Reduced from the prior range of $51 million to $53 million
- Cash and cash equivalents
- $3.7 million
- As of October 3, 2026
Previous Earnings Reports
-
Net loss narrowed and adjusted EBITDA was positive; 2026 revenue guidance was reaffirmed.
-
Revenue declined and net loss widened, while full-year revenue guidance was reaffirmed.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adjusted ebitda financial
stock-based compensation financial
convertible note financial
gaap financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 3, 2026.
Third Quarter 2026 Financial Highlights
- Generated total revenue of
$10.2 million , compared to$12.5 million in the prior year period - Cyclo G6® product family revenue was
$3.2 million , compared to$3.5 million in the prior year period- Sold approximately 11,900 Cyclo G6 probes compared to 14,900 in the prior year period
- Sold 28 Cyclo G6 Glaucoma Laser Systems compared to 30 in the prior year period
- Retina product revenue was
$5.1 million compared to$6.7 million in the prior year period - Gross margin increased to
42.4% , compared to32.1% in the prior year period and34.2% in the second quarter of 2026 - Completed headquarter relocation to San Jose, expected to deliver approximately
$600,000 in annualized savings
“On the top line, revenue came in below our expectations this quarter, driven by weaker than anticipated customer demand in Europe and Asia coupled with order delays late in the quarter as distributors worked through probe inventory and ongoing regulatory challenges. At the same time, we continue to experience the benefits from the cost savings programs initiated when I was named CEO, including the recent relocation of our headquarters,” said Patrick Mercer, President and CEO of Iridex.
“Considering the lower revenue and our investment in inventory to manage the manufacturing facility transition, cash utilization during the quarter was only
Third Quarter 2026 Financial Results
Total revenue for the three months ended October 3, 2026 was
Gross margin in the third quarter of 2026 was
Operating expenses were
Net loss was
Non-GAAP adjusted EBITDA loss for the third quarter of 2026 was
Cash and cash equivalents as of October 3, 2026 were
2026 Financial Outlook
Based on third quarter trends, which the Company expects to continue through the fourth quarter, the Company is reducing its annual revenue guidance for the full year 2026 to between
The Company continues to expect fiscal year 2026 adjusted operating expenses, which exclude depreciation and amortization and stock-based compensation, to be in the range of
Webcast and Conference Call Information
Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com or by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 7118799.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.
For additional information, visit www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning commercial trends, market adoption and expansion, expectations regarding profitability, demand for and utilization of the Company’s products, financial results and forecasts and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks further described in the “Risk Factors” section of Iridex’s most recent Annual Report on Form 10-K, as well as in Iridex’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Use of Non-GAAP Financial Information
This press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Management evaluates and makes operating decisions using various performance measures. In addition to Iridex’s GAAP results, we consider Adjusted EBITDA. This non-GAAP result should not be considered as an alternative to net income, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present this non-GAAP result because management considers it to be an important supplemental measure of Iridex’s performance and refers to such measures when analyzing Iridex’s strategy and operations. In calculating the above non-GAAP result: Adjusted EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Adjusted EBITDA exclude from their GAAP equivalents items listed below:
- Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Iridex.
- Severance-related expenses. We excluded from our non-GAAP results the expenses related to restructuring events, partially offset by reversals of previously recognized severance expenses in subsequent periods. These expenses are unrelated to our ongoing operations, vary in size and frequency and are subject to significant fluctuations from period to period due to varying levels of restructuring activity. We believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.
- Reconvention of shareholders’ meeting expenses. We excluded from our non-GAAP results the expenses related to the costs of reconvening our latest annual shareholders meeting. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.
- Legal settlement expenses. We excluded from our non-GAAP results the expenses related to the non-recurring settlement of a legal case regarding the use of tracking software on the Company’s website. We believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.
- Loss on write-down of inventory. We excluded from our non-GAAP results the expenses related to the write down of inventory related to the transfer of production of several products to 3rd party contract manufacturers. In these types of transactions, not all applicable inventories are acquired by the contract manufacturers and thus, such inventory becomes excess and obsolete. These expenses are unrelated to our ongoing operations, and we believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.
Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.
A detailed reconciliation between Iridex’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Iridex’s other reports filed with or furnished to the SEC.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
| IRIDEX Corporation Condensed Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| October 3, 2026 | September 27, 2025 | October 3, 2026 | September 27, 2025 | |||||||||||||
| Total revenues | $ | 10,156 | $ | 12,484 | $ | 34,521 | $ | 37,951 | ||||||||
| Cost of revenues | 5,854 | 8,471 | 21,182 | 24,201 | ||||||||||||
| Gross profit | 4,302 | 4,013 | 13,339 | 13,750 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 1,014 | 972 | 2,855 | 2,719 | ||||||||||||
| Sales and marketing | 2,408 | 2,657 | 7,492 | 7,645 | ||||||||||||
| General and administrative | 2,043 | 1,795 | 5,508 | 5,942 | ||||||||||||
| Total operating expenses | 5,465 | 5,424 | 15,855 | 16,306 | ||||||||||||
| Loss from operations | (1,163 | ) | (1,411 | ) | (2,516 | ) | (2,556 | ) | ||||||||
| Other expense, net | (160 | ) | (158 | ) | (469 | ) | (1,660 | ) | ||||||||
| Loss from operations before provision for income taxes | (1,323 | ) | (1,569 | ) | (2,985 | ) | (4,216 | ) | ||||||||
| Provision for income taxes | 78 | 4 | 206 | 37 | ||||||||||||
| Net loss | $ | (1,401 | ) | $ | (1,573 | ) | $ | (3,191 | ) | $ | (4,253 | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic | $ | (0.08 | ) | $ | (0.09 | ) | $ | (0.18 | ) | $ | (0.25 | ) | ||||
| Diluted | $ | (0.08 | ) | $ | (0.09 | ) | $ | (0.18 | ) | $ | (0.25 | ) | ||||
| Weighted average shares used in computing net loss per common share: | ||||||||||||||||
| Basic | 17,593 | 17,009 | 17,441 | 16,843 | ||||||||||||
| Diluted | 17,593 | 17,009 | 17,441 | 16,843 | ||||||||||||
| IRIDEX Corporation Condensed Consolidated Balance Sheets (In thousands) | ||||||||
| October 3, 2026 | January 3, 2026 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,673 | $ | 6,028 | ||||
| Accounts receivable, net | 4,775 | 9,545 | ||||||
| Inventories | 11,760 | 7,877 | ||||||
| Prepaid expenses and other current assets | 2,611 | 1,802 | ||||||
| Total current assets | 22,819 | 25,252 | ||||||
| Property and equipment, net | 210 | 58 | ||||||
| Intangible assets, net | 745 | 984 | ||||||
| Goodwill | 965 | 965 | ||||||
| Operating lease right-of-use assets, net | 3,615 | 768 | ||||||
| Other long-term assets | 918 | 1,124 | ||||||
| Total assets | $ | 29,272 | $ | 29,151 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 7,077 | $ | 5,502 | ||||
| Accrued compensation | 1,443 | 2,340 | ||||||
| Accrued expenses | 579 | 608 | ||||||
| Other current liabilities | 1,627 | 1,899 | ||||||
| Deferred revenue, current | 2,215 | 2,160 | ||||||
| Operating lease liabilities, current | 48 | 699 | ||||||
| Total current liabilities | 12,989 | 13,208 | ||||||
| Long-term liabilities: | ||||||||
| Deferred revenue | 5,702 | 6,801 | ||||||
| Operating lease liabilities | 3,561 | 98 | ||||||
| Convertible note payable | 3,825 | 3,735 | ||||||
| Other long-term liabilities | 568 | 387 | ||||||
| Total liabilities | 26,645 | 24,229 | ||||||
| Stockholders’ equity: | ||||||||
| Series B convertible preferred stock | 6,000 | 6,000 | ||||||
| Common stock | 178 | 174 | ||||||
| Additional paid-in capital | 92,100 | 91,208 | ||||||
| Accumulated other comprehensive loss | (14 | ) | (14 | ) | ||||
| Accumulated deficit | (95,637 | ) | (92,446 | ) | ||||
| Total stockholders’ equity | 2,627 | 4,922 | ||||||
| Total liabilities and stockholders’ equity | $ | 29,272 | $ | 29,151 | ||||
| IRIDEX Corporation Reconciliation of GAAP Net Loss to Adjusted EBITDA (In thousands) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| October 3, 2026 | September 27, 2025 | October 3, 2026 | September 27, 2025 | |||||||||||||
| Reconciliation of GAAP net loss to Adjusted EBITDA(a) | ||||||||||||||||
| GAAP net loss | $ | (1,401 | ) | $ | (1,573 | ) | $ | (3,191 | ) | $ | (4,253 | ) | ||||
| Interest income | (4 | ) | (10 | ) | (16 | ) | (31 | ) | ||||||||
| Other expense | 164 | 167 | 485 | 1,691 | ||||||||||||
| Provision for income taxes | 78 | 4 | 206 | 37 | ||||||||||||
| Nasdaq listing compliance | – | – | – | 152 | ||||||||||||
| Reconvention of shareholders’ meeting expenses | 67 | – | 129 | – | ||||||||||||
| Legal settlement expenses | – | – | 40 | – | ||||||||||||
| Depreciation and amortization | 260 | 366 | 994 | 1,125 | ||||||||||||
| Inventory write-down | – | 823 | – | 823 | ||||||||||||
| Stock-based compensation | 182 | 92 | 605 | 562 | ||||||||||||
| Severance related expense (for head count reduction) | 74 | – | 74 | 199 | ||||||||||||
| Adjusted EBITDA | $ | (580 | ) | $ | (131 | ) | $ | (674 | ) | $ | 305 | |||||
(a)Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as certain non-GAAP adjustments. | ||||||||||||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.